Mark Levis

33PUBLICATIONS

145CO-AUTHORS

Medical virologyMolecular targetsQuantum optics and quantum optomechanicsHaematological tumoursGroundwater hydrology

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (33)

Sort by Publication Date:

|Jun 04, 2026

ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia.

|Jun 01, 2026

Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.

|May 20, 2026

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.

|Apr 08, 2026

Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.

Mark J Levis, Harry P Erba, Pau Montesinos

|Feb 15, 2026

Chemotherapy regimens with second generation tyrosine kinase inhibitors for <i>BCR-ABL</i> B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.

John Preston Claiborne, Hua-Ling Tsai, Gabriel Ghiaur

|Oct 29, 2025

Conditioning, MRD, and NPM1 comutation in the MORPHO trial.

Mark J Levis, Mehdi Hamadani, Yi-Bin Chen

Pageof 6

Frequent Collaborators

11 joint publications

Alexander Perl

Yi-Bin Chen

Pau Montesinos

Mehdi Hamadani

Jason Hill

Hee-Je Kim

Celalettin Ustun

Andrew H Wei

Mark R Litzow

Masumi Ueda Oshima

Frequent Collaborators

11 joint publications

Alexander Perl

8 joint publications

Yi-Bin Chen

7 joint publications

Pau Montesinos

6 joint publications

Mehdi Hamadani